There’s been a lot in the news recently about the cardiovascular benefits of some of the newer, more expensive diabetes drugs, such as the SGLT-2 inhibitor class, which includes such brand-name drugs as Invokana and Jardiance. A recent study looked at two older, affordable, and commonly-prescribed types of drugs, to see how they compared. According to the researchers, “both pioglitazone and a sulfonylurea (glimepiride or gliclazide) as an add-on to metformin are associated with similarly low rates of cardiovascular events” and few side effects. Read more